Abstract | PURPOSE: METHODS: RESULTS: The median age of seizure onset was 23 months. About two-thirds of patients have focal seizures. Thirty-three patients use antiseizure medications. The mean duration of rapamycin treatment was 55.59 ± 18.42 months. Adverse reactions within 28 days after injection occurred in 11 patients (25%), all were under 12 years old. Injection site pain was the most reported event (20.45%), which was mild in severity and improved within one day. All patients had no seizure-related changes after vaccination. CONCLUSION:
|
Authors | Qian Lu, Yang-Yang Wang, Qiu-Hong Wang, Li-Na Tang, Xiao-Yan Yang, Shuo Dun, Li-Ping Zou |
Journal | Seizure
(Seizure)
Vol. 99
Pg. 71-74
(Jul 2022)
ISSN: 1532-2688 [Electronic] England |
PMID | 35605444
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- COVID-19 Vaccines
- MTOR Inhibitors
- TOR Serine-Threonine Kinases
- Sirolimus
|
Topics |
- Adolescent
- COVID-19
(prevention & control)
- COVID-19 Vaccines
(adverse effects)
- Child
- Child, Preschool
- Epilepsy
(chemically induced, drug therapy)
- Humans
- Infant
- MTOR Inhibitors
- Seizures
(drug therapy)
- Sirolimus
(adverse effects)
- TOR Serine-Threonine Kinases
- Tuberous Sclerosis
(complications, drug therapy)
|